Vinva Investment Management Ltd Raises Holdings in Amgen Inc. (NASDAQ:AMGN)

Vinva Investment Management Ltd increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 50.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,613 shares of the medical research company’s stock after acquiring an additional 7,264 shares during the period. Vinva Investment Management Ltd’s holdings in Amgen were worth $6,974,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of AMGN. Kennedy Capital Management LLC acquired a new position in shares of Amgen during the 1st quarter worth $3,240,000. LRI Investments LLC bought a new stake in Amgen in the first quarter valued at about $152,000. Redwood Grove Capital LLC increased its position in Amgen by 17.2% in the 1st quarter. Redwood Grove Capital LLC now owns 47,687 shares of the medical research company’s stock valued at $13,558,000 after acquiring an additional 7,000 shares during the period. Cetera Investment Advisers raised its stake in shares of Amgen by 268.9% during the first quarter. Cetera Investment Advisers now owns 233,379 shares of the medical research company’s stock valued at $66,355,000 after purchasing an additional 170,108 shares in the last quarter. Finally, Cetera Advisors LLC raised its position in shares of Amgen by 151.3% during the 1st quarter. Cetera Advisors LLC now owns 70,984 shares of the medical research company’s stock worth $20,182,000 after buying an additional 42,739 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. TD Cowen lifted their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada cut their price objective on Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research report on Wednesday. Truist Financial cut Amgen from a “buy” rating to a “hold” rating and lifted their target price for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Finally, Wolfe Research assumed coverage on Amgen in a report on Friday, November 15th. They set a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $323.05.

Amgen Stock Performance

Shares of AMGN opened at $280.07 on Thursday. The firm has a market cap of $150.55 billion, a price-to-earnings ratio of 35.86, a price-to-earnings-growth ratio of 2.62 and a beta of 0.60. The company’s fifty day moving average is $313.58 and its 200-day moving average is $317.57. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12 month low of $257.80 and a 12 month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the business posted $4.96 earnings per share. The business’s quarterly revenue was up 23.2% on a year-over-year basis. Equities analysts expect that Amgen Inc. will post 19.52 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.21%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.